ENXTBR:UCBPharmaceuticals
Assessing UCB (ENXTBR:UCB) Valuation After Positive PHOENYCS GO Phase 3 Lupus Results
UCB (ENXTBR:UCB) is back in focus after The Lancet published full Phase 3 PHOENYCS GO results for dapirolizumab pegol in moderate to severe systemic lupus erythematosus, highlighting statistically significant disease activity improvements and a favorable safety profile.
See our latest analysis for UCB.
The recent lupus data arrive after a strong run in UCB’s stock, with a 1 month share price return of 9.95% and a year to date share price return of 8.54%. The 1 year total shareholder return of...